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ABSTRACT
Objective  To determine whether spa therapy, plus 
home exercises and usual medical treatment provides 
any beneﬁ  t over exercises and usual treatment, in the 
management of knee osteoarthritis.
Methods  Large multicentre randomised prospective 
clinical trial of patients with knee osteoarthritis according 
to the American College of Rheumatology criteria, 
attending French spa resorts as outpatients between 
June 2006 and April 2007. Zelen randomisation was 
used so patients were ignorant of the other group 
and spa personnel were not told which patients were 
participating. The main endpoint criteria were patient 
self-assessed. All patients continued usual treatments 
and performed daily standardised home exercises. The 
spa therapy group also received 18 days of spa therapy 
(massages, showers, mud and pool sessions).
Main Endpoint  The number of patients achieving 
minimal clinically important improvement (MCII) at 6 
months, deﬁ  ned as ≥19.9 mm on the visual analogue 
pain scale and/or ≥9.1 points in a normalised Western 
Ontario and McMaster Universities osteoarthritis index 
function score and no knee surgery.
Results  The intention to treat analysis included 187 
controls and 195 spa therapy patients. At 6 months, 
99/195 (50.8%) spa group patients had MCII and 68/187 
(36.4%) controls (χ2=8.05; df=1; p=0.005). However, 
no improvement in quality of life (Short Form 36) or 
patient acceptable symptom state was observed at 6 
months.
Conclusion  For patients with knee osteoarthritis a 
3-week course of spa therapy together with home 
exercises and usual pharmacological treatments offers 
beneﬁ  t after 6 months compared with exercises and 
usual treatment alone, and is well tolerated.
Trial registration number  NCT00348777.
In Europe spa therapy is frequently prescribed for 
knee osteoarthritis. Of the 403 381 patients receiv-
ing spa therapy for rheumatism in 2007 in France, 
nearly half presented with knee osteoarthritis. 
Spa therapy is reimbursed by the social security 
in France and in many other continental European 
countries.
Despite numerous small scale studies, high qual-
ity scientiﬁ  c evidence for the efﬁ  cacy of spa ther-
apy for knee osteoarthritis is lacking. In a recent 
Cochrane systematic review, even those studies 
that met the selection criteria were found to be 
ﬂ  awed.1 Therefore, spa therapy does not ﬁ  gure 
in the recommended treatments of the European 
League Against Rheumatism2 or recent reviews.3
In this multicentre randomised controlled trial 
(RCT) we aimed to include enough patients to 
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obtain sufﬁ   cient statistical power to ﬁ   ll the gap 
in evidence-based data of high quality evaluating 
the use of spa therapy for knee osteoarthritis. Our 
primary objective was the therapeutic efﬁ  cacy of 
spa therapy for knee osteoarthritis at 6 months in 
patients following usual treatments and a home 
exercise programme compared with a control 
group receiving usual treatments and a home exer-
cise programme alone.
PATIENTS AND METHODS
This study was carried out in the three largest spa 
therapy resorts in France, Aix-les-Bains, Balaruc 
and Dax. In 2007, 29  000, 36  000 and 50  000 
  people, respectively, attended these three resorts 
for spa therapy. Patients were recruited locally, 
so that they could attend the centre on a daily 
basis, by advertisements in the regional press and 
posters in pharmacies and surgery waiting rooms.4 
Recruitment notices referred to treatment for knee 
osteoarthritis but did not specify spa therapy.
Patients were enrolled by a trained examining 
physician in private practice outside and indepen-
dent of the spa setting and with no vested interest 
in the spa. Osteoarthritis was conﬁ  rmed by phys-
ical examination and the presence of osteophytes 
on the x-rays.
Inclusion criteria followed the deﬁ  nitions of the 
American College of Rheumatology: painful knee 
osteoarthritis plus either age greater than 50 years 
and/or morning stiffness lasting more than 30 minutes 
and/or articular crepitation.5 The evidence required 
was a knee x-ray examination in the past 3 years, 
including anteroposterior, schuss, lateral and skyline 
views to grade the severity of osteoarthritis, and pain 
intensity of 30 mm or greater on the visual analogue 
pain scale (VAS pain).6
Exclusion criteria were: osteoarthritis limited 
to the patellofemoral joint; severe depression or 
psychosis; a contraindication (immune deﬁ  ciency, 
evolving cardiovascular conditions, cancer, infec-
tion) or intolerance to any aspect of spa treat-
ment; professional involvement with a spa resort; 
spa treatment within the previous 6 months; 
knee intrajoint corticosteroid injection within the 
past 3 months; massages, physiotherapy or acu-
puncture in the past month; a non-steroidal anti-
  inﬂ   ammatory drug (NSAID) within the past 5 
days or other analgesic drug in the previous 12 h, 
or a change in symptomatic slow-acting drugs in 
osteoarthritis (SYSADOA) in the past 3 months.
Intervention
At inclusion the examining physician explained the 
home exercise programme to all patients and the 
This paper is freely available 
online under the BMJ Journals 
unlocked scheme, see http://
ard.bmj.com/info/unlocked.dtl
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importance of performing all four exercises, each six times, three 
times a day.7 8 All patients were given a booklet about knee 
osteoarthritis with details of the home exercise programme 
(see supplementary ﬁ  le 1, available online only) and continued 
their usual treatments (analgesics, NSAID, SYSADOA, physio-
therapy). The self-assessment forms were completed without 
assistance in the waiting room.
In addition, the spa therapy group received 18 days of therapy 
over 3 weeks. The standardised knee osteoarthritis therapy pro-
gramme was designed by experienced spa therapy physicians. 
Spa mineral water and treatments are approved and controlled 
by the French authorities. Treatment included: mineral hydrojet 
sessions at 37°C for 15 minutes, manual massages of the knee 
and thigh under mineral water at 38°C by a physiotherapist for 
10 minutes, applications of mineral matured mud at 45°C to the 
knees for 15 minutes and supervised general mobilisation in a 
collective mineral water pool at 32°C in groups of six patients 
for 25 minutes.
Attendance, tolerance and proper performance of the various 
treatments were checked by an independent physician (general 
practitioner, rheumatologist or physiatrist) during consultations 
at the start, middle and end of the 3-week therapy period. Study 
patients were mixed with the general public and the centre per-
sonnel were not informed which patients were taking part in 
the clinical trial.
Patients in the control group were offered a 3-day wellness 
package at their local spa resort following the 6-month fol-
low-up visit.
Follow-up and data collection
Follow-up was at 1, 3 and 6 months, by a visit to the examin-
ing physician who completed the electronic case report form, 
enquired whether the patient was doing the exercises and 
insisted on their importance. At each visit, but not in the pres-
ence of the physician, the patients ﬁ  lled in self-assessment of: 
their average level of pain over the previous 7 days on the VAS 
pain scale,6 the Western Ontario and McMaster Universities 
osteoarthritis index (WOMAC)9 and the quality of life question-
naire, Short Form 36 (SF36),10 without assistance. At 9 months 
these forms were completed at home and returned to the coor-
dination centre by post.
The primary endpoint was achievement of a minimal clini-
cally important improvement (MCII)11 deﬁ  ned as 19.9 mm or 
greater on the VAS pain6 scale and/or 9.1 points or greater on the 
WOMAC function subscale normalised to a 0–100 score,9 and 
no knee surgery, at 6 months. For WOMAC we used a ﬁ  ve-point 
Likert scale for each item and higher scores indicated greater 
severity.11
Secondary endpoints were: patient acceptable symptom 
state,12 VAS pain 32 mm or less, normalised WOMAC function 
subscale 31 points or less; knee ﬂ  exion, effusion and swelling; 
associated treatments; the overall opinions of the patient and 
the examining physician and quality of life.
All items collected by the examining physician at baseline 
and during follow-up visits are listed in table 1 and online tables 
(supplementary ﬁ  le 2, available online only), respectively. All 
adverse events were recorded.
Design
The sample size was determined using an open preliminary 
study with 13 consecutive patients, from which we calculated 
that 50% would be improved in the spa group and estimated 
that 25% would be improved in the control group. The agreed 
Table 1  Baseline characteristics of participants
Characteristics Control Spa therapy
Male, n/N (%) 119/223 (53.4) 118/228 (51.8)
Age, mean±SD (n) 64.3±10.4 (223) 63.0±9.1 (228)
History of treatment for the knee
  Medication, n/N (%) 187/223 (83.9) 195/228 (85.5)
  Massage, n/N (%) 70/223 (31.4) 73/228 (32.0)
  Intra-articular injection, n/N (%) 51/223 (22.9) 59/228 (25.9)
  Hyaluronic acid treatment, n/N (%) 92/223 (41.3) 95/228 (41.7)
  Surgery, n/N (%) 82/223 (36.8) 81/228 (35.5)
  Previous spa therapy n/N (%) 74/218 (33.9) 61/227 (26.9)
    Other physical treatment, n/N (%) (brace, 
traction, manipulation or physiotherapy in 
past 3 months)
10/223 (4.5) 10/228 (4.4)
Prognostic factors
    Length of present episode, in months, 
mean±SD (n)
63.9±73.3 (223) 60.5±72.0 (228)
  Number of acute episodes, mean±SD (n) 7.8±10.5 (223) 8.6±16.9 (228)
  Family history of osteoarthritis, n/N (%) 116/223 (52.0) 117/228 (51.3)
  Body mass index, mean±SD (n) 29.0±4.6 (223) 30.7±5.9 (228)
Knee examination
  Knee joint swelling, n/N (%) 94/223 (42.2) 96/228 (42.1)
  Knee joint effusion, n/N (%) 62/223 (27.8) 58/228 (25.4)
    Knee joint crepitation on active motion, 
n/N (%)
107/223 (48.0) 107/228 (46.9)
Radiological severity (Kellgren and Lawrence), n/N(%)
  Grade 1 53/223 (23.8) 54/228 (23.7)
  Grade 2 70/223 (31.4) 73/228 (32.0)
  Grade 3 83/223 (37.2) 82/228 (36.0)
  Grade 4 17/223 (7.6) 19/228 (8.3)
WOMAC pain score, 0–100, mean±SD (n) 42.0±18.1 (223) 45.1±17.8 (224)
WOMAC function score, 0–100, 
mean±SD (n)
38.9±17.1 (218) 42.6±19.7 (214)
VAS pain, 0–100 mm, mean±SD (n) 45.7±19.0 (223) 49.9±20.2 (225)
PASS, n/N (%) 36/223 (16.1) 27/225 (12.0)
SF-36 scores
  Physical, mean±SD (n) 38.6±7.5 (216) 37.4±7.7 (216)
  Psychological, mean±SD (n) 46.6±10.0 (216) 46.2±11.5 (216)
Medication (at the time of inclusion)
  At least one medication, n/N (%) 110/223 (49.3) 117/228 (51.3)
  NSAID, n/N (%) 33/223 (14.8) 37/228 (16.2)
  SYSADOA, n/N (%) 58/223 (26.0) 52/228 (22.8)
  Analgesic, n/N (%) 49/223 (22.0) 62/228 (27.2)
  Hyaluronic acid, n/N (%) 1/223 (0.4) 1/228 (0.4)
PASS is the value beyond which patients can consider themselves well. It is 
composed of the VAS pain (cutoff ≤32 mm), the WOMAC function scores (cutoff 
≤31 mm) and the patient’s global self assessment of disease.
NSAID, non-steroidal anti-inﬂ  ammatory drug; PASS, patient acceptable symptom 
state; SF36, Short Form 36; SYSADOA, symptomatic slow acting drug in 
osteoarthritis; VAS, visual analogue scale; WOMAC, Western Ontario and McMaster 
Universities osteoarthritis index.
α risk was 5%, and the β risk was 20%. The number of patients 
was thus 58 per group per centre, or 67 allowing for 15% loss 
to follow-up.
The randomisation technique of Zelen was used.13 14 Eligible 
patients were randomly assigned to spa therapy or to the control 
group using a centralised computer programme. Randomisation 
was stratiﬁ  ed by centre and in blocks of eight with random 
order. Concealment was assumed by a protected computer ﬁ  le.
The Zelen randomisation method14 implied that patients 
were not informed of the existence of two groups. If the patient 
refused to participate as randomised, they were offered the 
other treatment, but remained in their assigned group for inten-
tion to treat analysis.
In order to conceal the existence of the other group,14 ran-
domisation was performed before written informed consent 
was obtained. Patients were told only about the group to which 
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from baseline to 6 months, divided by the SD of the baseline 
score.
For subgroup analyses a Mantel–Haenszel test of homogene-
ity was used. For the WOMAC and SF36 scores, missing data 
for each subscale were replaced by the mean of all the patients 
who had replied to at least half the questions in that subscale, 
according to the recommendations for SF36.10
Two-sided p values less than 0.05 were considered statisti-
cally signiﬁ  cant. Analyses were performed using STATA soft-
ware (version 10.0).
The trial protocol was passed favourably by the regional eth-
ics committee (Lyon A) in April 2006 and registered on http://
www.clinicaltrials.gov with number NCT00348777. Study coor-
dination, monitoring visits to each centre, data management, 
data entry from patient questionnaires and data analysis were 
performed by the Grenoble Clinical Research Centre.
RESULTS
The overall ﬂ  ow of patients included between June 2006 and 
April 2007 is shown in ﬁ  gure 1. In total, 7.2% (16/223) patients 
they had been assigned and were given one of the two possi-
ble patient information documents with the consent form. In 
addition, delocalisation of the consultation away from the spa 
setting was done with the intention of keeping patients ignorant 
of the other group.
Statistics
Analysis was performed by intention to treat. Categorical vari-
ables were expressed as frequency and percentage, continuous 
variables as mean and SD. The main endpoint was tested using 
an uncorrected χ2 test. Risk ratios with 95% CI, odds ratios and 
95% CI, number needed to treat and effect size with 95% CI 
were calculated.
Secondary qualitative endpoints were analysed using the same 
principles. For continuous variables, an analysis of variance was 
performed for repeated data, assuming sphericity, (comparison 
M0–M6 and M0–-M3–M6–M9) with a treatment factor and an 
interaction analysis (repetitions × treatment). Between-group 
comparisons at 6 months used Student’s t test. For WOMAC and 
VAS pain, the effect size was equal to the mean change in score 
Figure 1  Study ﬂ  ow chart. ITT, 
intention to treat. 630 Patients  examined
462 Patients randomised
(154 in each centre)
451 Patients  studied
168 Ineligible patients
223 Patients CONTROL
(Aix: 76, Balaruc: 71, Dax: 76)
￿ 207 Did not receive spa therapy
￿16 Changed to spa therapy group (Zelen)
228 Patients SPA THERAPY
(Aix: 77, Balaruc: 73, Dax: 78)
￿ 204 Received spa therapy
￿ 24 Changed to control group (Zelen)
11 Refused both groups (Zelen)
(5 spa therapy, 6 control)
- 27 Stopped the study  (17 withdrew 
consent + 10 other causes)
- 1 Lost to follow up
- 8 Questionnaires not returned 
at 6 months
- 25 Stopped the study
(13 withdrew consent + 
12 other causes)
- 2 Lost to follow up
- 6 Questionnaires not returned 
at 6 months
187 Patients with main end point 
at 6 months
(ITT analysis)
(Aix: 54, Balaruc: 59, Dax: 74 )
195 Patients with main endpoint 
at 6 months
(ITT analysis)
(Aix: 64, Balaruc: 63, Dax: 68 )
13 Questionnaires not
returned at 9 months
20 Questionnaires not 
returned at 9 months
174 Patients with at least 
one questionnaire 
returned by post at 9 months
175 Patients with at least 
one questionnaire
returned by post at 9 months
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Table 2  Number (%) of patients achieving MCII at 3, 6 and 9 months
Visit Control Spa therapy p Value
3 Months 70/179 (39.1%) 107/183 (58.5%)
6 Months 68/187 (36.4%) 99/195 (50.8%) 0.005
Details
  Improvement of VAS pain* 36/186 (19.4%) 63/193 (32.6%)
  Improvement of WOMAC function† 49/172 (28.5%) 75/179 (41.9%)
9 Months 62/173 (35.8%) 93/173 (53.8%)  
MCII is deﬁ  ned as ≥19.9 mm on the VAS pain scale and/or ≥9.1 points on the 
WOMAC function subscale normalised to a 0–100 score and no knee surgery.
*Three missing values for VAS pain.
†31 Missing values for WOMAC function.
MCII, minimal clinically important improvement; VAS, visual analogue scale; WOMAC, 
Western Ontario and McMaster Universities osteoarthritis index.
Table 3  Change in VAS pain and WOMAC scores (completed by the 
patient)
Difference: 6 months−inclusion
Control Spa therapy
p Value Mean±SD*
Effect size 
(95% CI) Mean±SD†
Effect size 
(95% CI)
VAS pain −4.0±22.8 
(n=186) 
0.21 
(0.01 to 0.42)
−11.4±24.9 
(n=193) 
0.55 
(0.35 to 0.75)
0.003
WOMAC 
function
−3.0±15.4 
(n=172) 
0.17 
(−0.04 to 0.38)
−8.5±14.7, 
(n=179) 
0.43 
(0.22 to 0.64)
<0.001
*Three missing values for VAS pain.
†31 missing values for WOMAC.
VAS, visual analogue scale; WOMAC, Western Ontario and McMaster Universities 
osteoarthritis index.
changed from the control to the spa group, and 10.5% (24/228) 
changed from the spa group to the control group. Thirteen 
patients in the spa group withdrew consent to participate before 
starting the sessions. Of 12 who dropped out, mainly for health 
or family reasons, only two had started spa sessions. In the con-
trol group, 17 patients withdrew consent and another 10 failed 
to attend study visits.
Main endpoint
The difference in MCII at 6 months is statistically signiﬁ  cant 
(χ2=8.05; df=1; p=0.005) in favour of spa therapy (table 2). Three 
patients in the spa group and one in the control group achieved 
MCII but underwent knee prosthesis surgery during the study. 
They were considered to be treatment failures. The risk ratio of 
MCII is 1.4 (95% CI 1.1 to 1.8) for the spa group versus control, 
the odds ratio 1.8 (95% CI 1.2 to 2.8), and the number needed 
to treat is 6.9 patients.
Secondary endpoints
The secondary endpoint results are internally coherent with 
the effect size found for the components of the main endpoint 
(tables 3 and 4 and further details online in supplementary ﬁ  le 2, 
available online only).
Planned subgroup analyses, sensitivity analysis and unplanned 
post-hoc analyses
See online supplementary ﬁ  le 2 (available online only).
Adverse events
One patient in the spa group was hospitalised for urinary lithia-
sis, no other unexpected serious adverse event was reported. For 
adverse events see supplementary ﬁ  le 2, available online only.
DISCUSSION
This study demonstrates that an intensive course of spa therapy 
with a home exercise programme and usual treatment provides 
medium-term beneﬁ   t over a home exercise programme and 
usual treatment alone in the management of knee osteoarthritis
To our knowledge this is the ﬁ  rst multicentre RCT of spa ther-
apy for knee osteoarthritis. The study size attains the number 
of patients (498) combined from seven smaller heterogeneous 
studies in a recent systematic Cochrane review.1
We used the Zelen randomisation method to blind patients 
in one group to the existence of the other group and to limit 
the level of dropout. It allowed patients assigned to spa therapy 
who did not want the constraint of having to attend a spa for 3 
weeks, to change to the control group. The possibility to change 
could potentially reduce the difference between the two treat-
ments as the intention to treat analysis was performed accord-
ing to randomisation status.
We did not attempt to assess the efﬁ  cacy of spa therapy alone, 
but only in combination with a home exercise programme and 
usual medical treatment. Both groups thus adhered to the cur-
rent recommendations for the treatment of knee osteoarthritis.3 
15 16 We minimised a ‘placebo’ effect in the control group, who 
were followed up in the same way as the spa group.17 The use 
of a qualitative endpoint measure, the MCII, may also reduce 
the inﬂ  uence of a potential ‘placebo effect’.18
Our main endpoint, MCII, is clinically relevant to the patient, 
comprising change in the WOMAC function subscale and 
VAS pain measurement, both recognised validated endpoint 
measures.
According to the recommendations for non-pharmacological 
trials,19 we used Zelen randomisation, employed examining 
physicians independent of the spa setting and patient self-as-
sessed primary endpoint measures.
The amplitude of our result is in line with our hypothesis when 
we calculated the sample size needed for this study. Our effect 
sizes are similar to those for other treatments of knee osteo-
arthritis including hyaluronic acid, paracetamol and NSAID.20–22
Although only three patients were completely lost to fol-
low-up, 52 patients withdrew consent or dropped out early on 
and 14 patients failed to return the questionnaires at 6 months, 
leading to a reduced number of patients or data in the main end-
point analysis at 6 months.
Our three centres receive approximately 30% of patients 
attending a spa in France. The standardised therapy delivered to 
osteoarthritis patients is similar to treatments delivered in other 
European spa settings.
The effect of spa therapy might be explained by that of a holi-
day. This was not the case here, patients had to drive daily to the 
spa, unlike those in a recent study by Karagülle et al.23 In France 
26% of patients attend spa therapy on an outpatient basis, the 
rest staying on site for the duration of the course.
In general, our results conﬁ  rm those already observed in other 
studies of a smaller size undertaken in a spa setting with natural 
hot mineral waters. Comparisons between the various studies are 
difﬁ  cult as the baseline proﬁ  les of the patients are heterogeneous, 
the interventions differ in type, intensity and in length,24–33 the 
methods used for the assessment of efﬁ  cacy vary and patients 
have been assessed at different time points after therapy.
At inclusion the severity of osteoarthritis in our patients was 
comparable to patients in the study advocating the use of MCII 
as an endpoint measure.11
This study attempts to assess the medium-term effect of spa 
therapy rather than simply short-term relief. Signiﬁ  cant relief 
from pain at shorter time points after therapy compared with 
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2002;21:218–21.
25.  Sukenik S, Flusser D, Codish S, et al. Balneotherapy at the Dead Sea area for knee 
osteoarthritis. Isr Med Assoc J 1999;1:83–5.
26.  Green J, McKenna F, Redfern EJ, et al. Home exercises are as effective as outpatient 
hydrotherapy for osteoarthritis of the hip. Br J Rheumatol 1993;32:812–15.
27.  Tishler M, Rosenberg O, Levy O, et al. The effect of balneotherapy on osteoarthritis. 
Is an intermittent regimen effective? Eur J Intern Med 2004;15:93–6.
28.  Obadasi E, Karagülle MZ, Karagülle Z, et al. Comparison of two spa therapy regimens 
in patients with knee osteoarthritis, an exploratory study. Phys Med Rehab Kuror 
2002;12:337–41.
29.  Evcik D, Kavuncu V, Yeter A, et al. The efﬁ  cacy of balneotherapy and mud-pack 
therapy in patients with knee osteoarthritis. Joint Bone Spine 2007;74:60–5.
30.  Wigler I, Elkayam O, Paran D, et al. Spa therapy for gonarthrosis: a prospective study. 
Rheumatol Int 1995;15:65–8.
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control is reported in other studies.27 28 32 34 Our encouraging 
results obtained at 6 months appear to persist at least until 9 
months.
What is the place of thermal spa therapy in the management 
of knee osteoarthritis? A recent high quality RCT demonstrated 
that arthroscopy of the knee has no lasting effect on knee osteo-
arthritis.35 Likewise, acupuncture plus a course of advice and a 
home exercise programme showed no signiﬁ  cant effect of real 
acupuncture at 6 months follow-up.36 Spa therapy appears to 
provide some beneﬁ  t.
A physical exercise regimen has been shown to be effective 
for knee osteoarthritis. Nevertheless, it is well known that unsu-
pervised home exercise programmes often have limited efﬁ  cacy 
over time as a result of progressive lack of compliance, even 
in the context of therapeutic trials with consecutive visits and 
that are motivating for the patients.4 37 A course of spa therapy 
may thus enhance patient compliance to the home exercise 
programme.
In conclusion, this RCT argues in favour of a clinical effect 
of spa therapy, as practised in France, for patients with knee 
osteoarthritis who continue their usual medical treatment and 
are encouraged to do regular exercises at home. In addition spa 
therapy is well tolerated.
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